Last reviewed · How we verify
ABT-333
ABT-333 is a non-nucleoside inhibitor of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase that blocks viral replication.
ABT-333 is a non-nucleoside inhibitor of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase that blocks viral replication. Used for Chronic hepatitis C virus infection (genotype 1).
At a glance
| Generic name | ABT-333 |
|---|---|
| Also known as | dasabuvir, Dasabuvir, ABT-333 also known as dasabuvir, ABT-333 also known as Exviera, ABT-333 |
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | Non-nucleoside NS5B polymerase inhibitor |
| Target | HCV NS5B RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
ABT-333 binds to the NS5B polymerase enzyme of HCV, preventing the virus from synthesizing new RNA and replicating. It was developed as part of AbbVie's direct-acting antiviral (DAA) portfolio for hepatitis C treatment, often used in combination with other DAAs to achieve sustained virologic response.
Approved indications
- Chronic hepatitis C virus infection (genotype 1)
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment (PHASE4)
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (PHASE3)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- Study of Oral Treatments for Hepatitis C (PHASE4)
- Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-333 CI brief — competitive landscape report
- ABT-333 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI